Trials / Completed
CompletedNCT03225352
A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets
An Open Label, Randomized, Four-Way Crossover Trial to Assess the Disintegration, Gastric Emptying and Pharmacokinetic Parameters of a New Disintegrating Acetylsalicylic Acid 500 mg, 1000 mg Tablet Formulation and 2 Different Ibuprofen Tablets in Fasted Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to assess disintegration of the new Aspirin disintegrating tablets
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 500 mg acetylsalicylic acid (Aspirin, BAYE4465) | Single intake of 1 tablet, 500mg |
| DRUG | 1000 mg acetylsalicylic acid (Aspirin, BAYE4465) | Single intake of 1 tablet, 1000mg |
| DRUG | 400 mg ibuprofen(Nurofen) | Single intake of 1 tablet, 400mg |
| DRUG | 400 mg ibuprofen (Dolormin Extra) | Single intake of 1 tablet, 400mg |
Timeline
- Start date
- 2017-08-07
- Primary completion
- 2017-10-07
- Completion
- 2017-10-16
- First posted
- 2017-07-21
- Last updated
- 2018-06-06
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03225352. Inclusion in this directory is not an endorsement.